gene_symbol
SLAMF7
hgnc_id
HGNC:21394
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
Elotuzumab binds SLAMF7 on myeloma cells and engages/activates NK cells via Fc gamma receptors (CD16) and SLAMF7 on NK cells, triggering antibody-dependent cellular cytotoxicity to lyse SLAMF7+ tumor cells.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Also known as CS1/CRACC; surface glycoprotein expressed on myeloma and NK cells
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06518551
disease_id_num_tar_ref
440
drug_id_num_tar_ref
1239